Objective:

To examine AI-driven innovations in personalized medicine and drug design, with a specific focus on inventorship issues that directly affect pharmaceutical patent protection.

Approach:

Key Findings:

• AI is transforming drug discovery and personalized medicine, raising complex IP challenges.
• The US legal framework for inventorship does not currently accommodate AI as a legal inventor, which complicates patent protection.
• Comparative approaches in Germany and China may offer insights for US stakeholders navigating these challenges.

Interpretation:

The evolving role of AI in pharmaceuticals necessitates a reevaluation of existing IP frameworks to address inventorship and copyright issues.

Limitations:

• The review primarily focuses on US, German, and Chinese legal contexts, which may not be universally applicable and could limit the generalizability of the findings.
• Specific case studies and examples may not cover the full spectrum of AI applications in pharmaceuticals.

Conclusion:

AI's integration into pharmaceuticals presents significant IP challenges that require careful navigation within existing legal frameworks.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.